Gilead links with Sangamo in gene therapy alliance – PharmaTimes
PharmaTimes |
Gilead links with Sangamo in gene therapy alliance
PharmaTimes Gilead's Kite is linking with Sangamo Therapeutics in a collaboration that aims to develop next-generation engineered cell therapies for the treatment of cancer. Kite will use Sangamo's ZFN technology gene therapies for autologous and allogeneic use in … Kite, Sangamo Launch Up-to-$3B+ Cancer Cell Therapy Partnership Sangamo in $3 billion gene-editing deal with Gilead Kite and Sangamo come together in $3bn cancer gene editing alliance |
